The Global Cancer Vaccines Market size was USD 9.69 billion in 2023 and it is expected to grow to USD 17.86 billion in 2031 with a CAGR of 10.55% in the 2024-2031 period.

1. Global Cancer Vaccines Market Size, Share, Growth &
Trends Analysis Report By Technology (mRNA-based
Cancer Vaccines, Vector-based Cancer Vaccines,
Dendritic Cell Cancer Vaccines, Tumor Antigen
Cancer Vaccines) By Type of Cancer (Breast Cancer,
Prostate Cancer, Lung Cancer, Cervical Cancer,
Colorectal Cancer, Other Cancer Types) By Type of
Vaccine (Preventive (Prophylactic) Vaccines,
Therapeutic (Treatment) Vaccines) By End-User
(Hospitals, Cancer Research Institutes, Clinics,
Ambulatory Surgical Centers): Regional Outlook,
Growth Potential and Segments Forecast 2024-2030
SKU: 014
Published Date: April 2024
No. of Pages: 200
Categories: Pharmaceutical
Summary of Report:
The Global Cancer Vaccines Market size
was USD 9.69 billion in 2023 and it is expected
to grow to USD 17.86 billion in 2031 with
a CAGR of 10.55% in the 2024-2031 period.
Global Cancer Vaccines Market Size, Share,
Growth & Trends Analysis Report By
Technology (mRNA-based Cancer Vaccines,
Vector-based Cancer Vaccines, Dendritic Cell
Cancer Vaccines, Tumor Antigen Cancer
Vaccines) By Type of Cancer (Breast Cancer,
Prostate Cancer, Lung Cancer, Cervical Cancer,
Colorectal Cancer, Other Cancer Types) By
Type of Vaccine (Preventive (Prophylactic)
Vaccines, Therapeutic (Treatment) Vaccines)
By End-User (Hospitals, Cancer Research
Institutes, Clinics, Ambulatory Surgical
Centers): Regional Outlook, Growth Potential and Segments Forecast 2024-2030 quantity
BUY NOW
Request Sample
Pre-Order Inquiry
Request Discount

2. Description
Global Cancer Vaccines Market: Overview
The global cancer vaccines market is the industry encompassing the development, production, and
distribution of vaccines specifically designed for the prevention or treatment of cancer. This market is a
dynamic and rapidly growing field within the broader healthcare landscape. Advancements in
immunological research and vaccine technologies are leading to the development of more targeted and
effective cancer vaccines. This includes personalized vaccines tailored to individual patients, as well as
novel delivery methods and therapeutic approaches.
There is a growing emphasis on preventive healthcare and early intervention strategies in cancer
management. This trend favours the adoption of cancer vaccines, particularly those with prophylactic
capabilities. The global incidence and mortality rates of cancer are steadily increasing, creating a pressing
need for effective preventive and therapeutic strategies. Cancer vaccines offer a promising avenue to
address this growing public health challenge.
Global Cancer Vaccines Market: Covid-19 Impact
The global focus on COVID-19 vaccines has potentially increased public awareness and acceptance of
vaccination in general, which could benefit the adoption of cancer vaccines in the future. The pandemic
has spurred rapid advancements in vaccine development and manufacturing technologies, which could
benefit the development of new cancer vaccines. The increased use of telehealth during the pandemic may
improve access to cancer care and facilitate patient participation in clinical trials for cancer vaccines.
Many cancer vaccine clinical trials were delayed or halted due to the pandemic, hindering research and
development progress. The focus on COVID-19 response diverted resources and attention away from other
healthcare priorities, including cancer research and treatment. Fear of COVID-19 exposure and disruptions
to healthcare services led to a decline in cancer screenings and diagnoses, potentially delaying cancer
detection and treatment.
Overall, the COVID-19 pandemic has had a mixed impact on the global cancer vaccines market. While it
has presented challenges, it has also highlighted the importance of cancer research and vaccine
development and potentially paved the way for future advancements in the field.
Global Cancer Vaccines Market: Growth Drivers
1. Rising Cancer Incidence:
The global prevalence of cancer continues to rise, driving the need for effective treatments. Cancer
vaccines offer a promising avenue for prevention and treatment, contributing to the growing demand for
such therapies.
2. Advancements in Immunotherapy:
Immunotherapy, including cancer vaccines, has witnessed significant advancements. The success of
immune checkpoint inhibitors and CAR-T cell therapies has spurred interest in developing vaccines that
harness the body’s immune system to target and eliminate cancer cells.
3. Focus on Personalized Medicine::
The trend towards personalized medicine emphasizes the development of targeted therapies tailored to
individual patients. Cancer vaccines, especially those designed to target specific tumor antigens, align with
the principles of personalized medicine.
Global Cancer Vaccines Market: Restraining factors
1. Complexity of Cancer Immunology:
Understanding the complex interactions between cancer cells and the immune system poses challenges.
The intricate nature of cancer immunology makes it difficult to design vaccines that consistently produce
strong and durable anti-cancer responses.
2. Limited Efficacy in Some Cancers:
The effectiveness of cancer vaccines can vary among different types of cancers. Some tumors may not
respond well to immunotherapy, including vaccines, leading to limitations in the scope of application for
certain cancer types.
Global Cancer Vaccines Market: Opportunity factors
1. Expanding Indications and Targets:

3. Identifying new tumor antigens and expanding the range of cancer types that can be targeted by vaccines
present opportunities for market growth. Research efforts focusing on a broader spectrum of cancers could
lead to the development of more effective vaccines.
2. Combination Therapies with Other Immunotherapies:
Exploring combination therapies involving cancer vaccines and other immunotherapies, such as immune
checkpoint inhibitors, may enhance treatment outcomes. Synergistic effects could lead to improved
efficacy and a broader application in different cancer types.
Global Cancer Vaccines Market: Challenges
1. Tumor Heterogeneity:
Tumor heterogeneity, where cancer cells within a single tumor may have different genetic profiles, poses a
challenge. Developing vaccines that effectively target this heterogeneity and address the diversity of
cancer cells is a complex task.
2. Immune Suppression in the Tumor Microenvironment:
The tumor microenvironment can create an immunosuppressive environment, hindering the immune
response generated by cancer vaccines. Overcoming the immunosuppressive nature of tumors is a
significant challenge in developing effective vaccines.
Global Cancer Vaccines Market: Segmentation
 Based On Type of Cancer: The market is segmented into Breast Cancer, Prostate Cancer, Lung
Cancer, Cervical Cancer, Colorectal Cancer and Others. Among these the Cervical cancer is the
leading cause of cancer death worldwide, with millions of new cases diagnosed each year.
 Based On Technology: The market is segmented into mRNA-based Cancer Vaccines, Vector-based
Cancer Vaccines, Dendritic Cell Cancer Vaccines and Tumor Antigen Cancer Vaccines. Among
these Tumor antigen cancer vaccines currently hold the majority of the revenue share.
 Based On Type of Vaccine: Based on Type of Vaccine segmentation, the market is further divided
into Preventive (Prophylactic) Vaccines and Therapeutic (Treatment) Vaccines. Among these, the
Preventive (Prophylactic) Vaccines contributes largest revenue share.
 Based On End-User: Based on End-User segmentation, the market is further divided into Hospitals,
Ambulatory Surgical Centers (ASCs), and Clinics. Among these, the Hospitals contributes largest
revenue share.
 Based On Region: Based on Region, the market is segmented into five key geographical regions
namely – North America, Europe, Asia Pacific, Latin America, and Middle East & Africa.
Global Cancer Vaccines Market: Regional Insights
1. North America
North America currently holds the largest market share due to factors like high healthcare spending and
extensive vaccination programs favor cancer vaccine adoption. Significant prevalence of various cancers,
particularly breast, lung, and prostate, creates a large market demand. Leading pharmaceutical companies
and research institutions drive innovation in the field.
2. Europe
Europe follows North America in market size, driven by factors like strong public healthcare infrastructure
and government initiatives promoting vaccine access. Growing emphasis on personalized cancer
treatments creates opportunities for tailored vaccines. Rising cancer incidence among the aging population
fuels market growth.
3. Asia-Pacific
Asia Pacific demonstrates the highest growth potential due to a vast and rapidly growing populations with
increasing cancer rates offer significant market potential. Increasing disposable income and investments in
healthcare infrastructure improve access to vaccines. Countries like China and India are witnessing rapid
advancements in cancer research and vaccine development.
4. Latin America
Latin America holds significant potential for market growth, public and private healthcare investments are
improving access to cancer treatment and preventive measures. Growing awareness about cancer and its
prevention is leading to increased demand for vaccines. Some countries are implementing national
vaccination programs, particularly for HPV vaccines.
5. Middle East and Africa

4. The MEA region currently holds the smallest market share, but it is expected to see modest growth in the
coming years. Increasing cancer incidence rates, particularly in certain regions, create market demand.
Growing urban populations and lifestyle changes are associated with higher cancer risks. Investments in
healthcare infrastructure are slowly improving access to cancer treatment and prevention options.
Global Cancer Vaccines Market: Competitive Landscape
 Vaccinogen, Inc.,
 GlaxoSmithKline plc (GSK),
 Merck & Co., Inc.,
 Advaxis Inc.,
 Amgen Inc.,
 Immunocellular Therapeutics, Ltd,
 Generex Biotechnology Corporation,
 Dynavax Technologies Corporation,
 F Hoffmann-La Roche AG,
 Moderna Inc.
Global Cancer Vaccines Market: Recent Developments
 F Hoffmann-La Roche AG: In December 2023, Roche partners with ElevateBio to develop and
commercialize novel T-cell receptor (TCR) therapies for cancer treatment.
 Generex Biotechnology Corporation: In July 2023, Announced a definitive agreement to acquire
NuGenerex Immuno-Oncology, Inc., a clinical-stage biotechnology company developing a Ii-Key T
cell vaccine platform for cancer and infectious diseases.